RV328/ AIDSVAX
Status:Ongoing
Phase:II
Principal Investigator(s):Nittaya Phanuphak
Objective:The purpose of this study is to define the immune responses induced by a HIV vaccine, AIDSVAX B/E. Blood and mucosal samples will be collected to assess immune responses.
Last updated February 26, 2021
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
DescriptionAIDSVAX B/E at Weeks 0, 4, 24 and 48
Mode of Delivery
ARMsExperimental
Official Code:
NCT01933685
Trial Sponsors:
NIH, USAMRDC
Start Date
End Date
July 9, 2014
May 1, 2020
Enrollment:40
Age range:
20 Years ↔
40 Years
Population:Cisgender Men, Cisgender Women